BlueWind Medical Announces Category I CPT Code for Subfascial Tibial Neuromodulation
BlueWind Medical Announces Category I CPT Code for Subfascial Tibial Neuromodulation
BlueWind Medical, developer of the Revi® System for urgency urinary incontinence (UUI), today announced that the American Medical Association (AMA) CPT® Editorial Panel has approved a new Category I CPT code for subfascial implantation of a tibial neuromodulation device. The new code takes effect January 1, 2028.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002313105/en/
credit: BlueWind Medical Revi System
Revi has demonstrated durable results with efficacy of 79% at three years and 95% patient satisfaction. Designed for a 15-year implant life, the miniature device is placed near the ankle in an outpatient procedure under local anesthesia. Patients receive personalized therapy at home that is powered using a lightweight external wearable transmitter.
Revi offers patients the ability to control when to activate their therapy and the amount of therapy they desire along with the added benefit of not requiring frequent device replacement due to short battery life.
The new Category I code recognizes the distinct physician work and procedural complexity involved in subfascial implantation, differentiating it from subcutaneous placement of a tibial neuromodulation device. Revi’s subfascial placement positions the implant in close proximity to the tibial nerve. Due to the elegant nature of the implant procedure, Revi can safely be implanted in an Ambulatory Surgery Center or hospital outpatient department.
Separate codes for subfascial and subcutaneous implantation will also allow payers to distinguish the procedures in claims data, supporting long-term tracking and comparison of outcomes associated with each approach when linked with clinical data.
“This coding milestone and the differentiation between subfascial and subcutaneous procedures in the coding structure reflects the AMA’s recognition of the distinct work physicians perform for subfascial placement. Subfascial placement, which places the device closer to the tibial nerve, along with Revi’s durable clinical outcomes, are attributes that distinguish Revi for patients,” said Kerry Nelson, Chief Executive Officer of BlueWind Medical. “With 79% efficacy at three years, 95% patient satisfaction and a device designed for a 15-year implant life, Revi offers a compelling long-term treatment option. We are grateful to the physicians and our professional society partners whose expertise, advocacy and support helped make this milestone possible.”
Physician Input Is the Next Step
The next step in the process is a physician survey conducted through the AMA/Specialty Society RVS Update Committee (RUC) process. Participating urologists will have an opportunity to provide input on the time, intensity and complexity of the physician work required for subfascial implantation. Those responses will inform recommendations to the Centers for Medicare & Medicaid Services regarding physician payment valuation.
“Urologists have an important opportunity to help ensure that the work involved in this procedure is accurately represented,” added Dr. Roger Dmochowski, BlueWind Medical’s Chief Medical Officer. “We encourage physicians selected to participate to complete the survey and share their experience with subfascial placement.”
The Category I code establishes a distinct reporting pathway for the procedure. Payment rates and payer coverage policies will be determined separately.
About the Revi System
The Revi® System is an FDA-approved tibial neuromodulation treatment for urgency urinary incontinence. Its miniature implant is placed near the ankle and powered by a lightweight external wearable that patients use to receive personalized therapy at home. Designed for a 15-year implant life, Revi avoids the need for implanted battery replacements and repeated office visits for routine treatment.
About BlueWind Medical
BlueWind Medical is a medical device company focused on advancing treatment for urgency urinary incontinence. Through the Revi System, the company aims to provide durable symptom relief with a simple implantation procedure and personalized therapy that fits into patients’ daily lives.
For more information, visit https://bluewindmedical.com
Media Contact
press@bluewindmedical.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20261002313105/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
What’s Ahead for Stocks This Quarter—and Where to Invest
United States